Involved field(IF) vs. extended field (EF) radiotherapy (RT) for patients in early unfavorable stages of Hodgkin's lymphoma (HL): 10-year update of the HD8 trial of the German Hodgkin Study Group (GHSG)

被引：0
|
作者：
Kriz, J. [1 ]
Sasse, S. [2 ]
Klimm, B. [2 ]
Goergen, H. [2 ]
Mueller, R. -P [3 ]
Diehl, V [2 ]
Borchmann, P. [2 ]
Engert, A. [2 ]
Eich, H. -T [1 ]
机构：
[1] Univ Munster, Klin Strahlentherapie, Munster, Germany
[2] Uniklin Koln, Innere Med Klin 1, Cologne, Germany
[3] Uniklin Koln, Klin Strahlentherapie, Cologne, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2012年 / 188卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：30 / 30
页数：1
相关论文
共 50 条
  • [41] Comparison of 30 Gy versus 20 Gy involved field radiotherapy after two versus four cycles ABVD in early stage Hodgkin's lymphoma: Interim analysis of the German Hodgkin study group trial HDIO
    Eich, H
    Mueller, R
    Engert, A
    Hansemann, K
    Skripnitchenko, R
    Pfistner, B
    Lukas, P
    Willich, N
    Diehl, V
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S1 - S2
  • [42] DOSE-INTENSIFIED COMBINED MODALITY TREATMENT WITH 2 CYCLES OF BEACOPP ESCALATED FOLLOWED BY 2 CYCLES OF ABVD AND INVOLVED FIELD RADIOTHERAPY (IF-RT) IS SUPERIOR TO 4 CYCLES OF ABVD AND IF-RT IN PATIENTS WITH EARLY UNFAVOURABLE HODGKIN LYMPHOMA (HL): AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHS)
    Engert, M.
    Borchmann, P.
    Pluetschow, A.
    Fuchs, M.
    Markova, J.
    Lohri, A.
    Kral, Z.
    Greil, R.
    Topp, M. S.
    Villalobos, M.
    Zijlstra, J. M.
    Soekler, M.
    Stein, H.
    Eich, H. -T
    Mueller, R. -P
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 226 - 226
  • [43] Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial
    Baues, Christian
    Goergen, Helen
    Fuchs, Michael
    Rosenbrock, Johannes
    Celik, Eren
    Eich, Hans
    Kobe, Carsten
    Voltin, Conrad-Amadeus
    Engert, Andreas
    Borchmann, Peter
    Marnitz, Simone
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (04): : 900 - 906
  • [44] Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG)
    Diehl, V.
    Haverkamp, H.
    Mueller, R.
    Mueller-Hermelink, H.
    Cerny, T.
    Markova, J.
    Ho, A. D.
    Kanz, L.
    Greil, R.
    Engert, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and Involved Field Radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the GHSG HD14 trial
    Eich, H. T.
    Borchmann, P.
    Kriz, J.
    Pluetschow, A.
    Fuchs, M.
    Engert, A.
    Mueller, R. -P.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 : 77 - 77
  • [46] Minimal initial chemotherapy plus involved field radiotherapy (RT) versus mantle field RT for clinical stage IA/IIA supra-diaphragmatic Hodgkin's disease (HD). Results of the UK Lymphoma Group LY07 trial.
    Radford, J
    Williams, MV
    Hancock, BW
    Hoskin, P
    Sun-Mynt, H
    Smith, P
    Qian, W
    Linch, D
    BRITISH JOURNAL OF CANCER, 2004, 91 : S1 - S1
  • [47] Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
    Rosenbrock, Johannes
    Kaul, Helen
    Oertel, Michael
    Celik, Eren
    Linde, Philipp
    Fan, Jiaqi
    Eichenauer, Dennis A.
    Broeckelmann, Paul J.
    von Tresckow, Bastian
    Kobe, Carsten
    Dietlein, Markus
    Fuchs, Michael
    Borchmann, Peter
    Eich, Hans Theodor
    Baues, Christian
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (05): : 1344 - 1352
  • [48] Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated followed by 4 Cycles of BEACOPP Baseline with or without Radiotherapy in Patients in Advanced-stage Hodgkin Lymphoma (HL): Final Analysis of the Randomized HD12 Trial of the German Hodgkin Study Group (GHSG)
    Eich, H.
    Engert, A.
    Haverkamp, H.
    Staar, S.
    Kriz, J.
    Engenhart-Cabillic, R.
    Lukas, P.
    Willich, N.
    Diehl, V.
    Mueller, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S3 - S4
  • [49] Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with our without radiotherapy in patients in advanced stage Hodgkin Lymphoma (HL): Final analysis of the randomised HD12 trial of the German Hodgkin Study Group (GHSG)
    Eich, H. T.
    Mueller, R-P.
    Haverkamp, H.
    Gossmann, A.
    Staar, S.
    Kriz, J.
    Lukas, P.
    Willich, N.
    Engenhart-Cabillic, R.
    Engert, A.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 : 26 - 26
  • [50] Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG)
    Diehl, Volker
    Haverkamp, Heinz
    Mueller, Rolf Peter
    Eich, Hans Theodor
    Mueller-Hermelink, Hans Konrad
    Cerny, Thomas
    Markova, Jana
    Ho, Anthony
    Kanz, Lothar
    Greil, Richard
    Hiddemann, Wolfgang
    Engert, Andreas
    BLOOD, 2008, 112 (11) : 552 - 553
12345